The new study lays the foundation for targeted removal of leukemia stem cells

leukemia is caused by leukemia stem cells, which are resistant to most known treatments. Recurrence is also caused by this resistance. Leukemia stem cells come from normal hematopoietic stem cells. Because of their close relationship, leukemia stem cells and hematopoietic stem cells have many of the same signal transducting pathways. If you want to stop the proliferation of leukemia stem cells, the key is to find a signaling path that is active only in leukemia stem cells, not in normal hematopoietic stem cells. To that goal, Professor Adrian Ochsenbein of the University of Bern in Switzerland and his team are working in the Department of Medical Oncology at Inselspital, a university hospital in Bern. Their latest light/LTbR path was published in the journal Nature Communications on February 16, 2021 under the title "LIGHT/LT beta signaling regulators self-renewal and derivion of hematopoietic and leukemia cell stems".A new method of controlling leukemia stem cellslight/LT betaR signaling path path is not effective in hematopoietic stem cells during normal blood formation. It plays an important role in maintaining stem cell function only when demand increases, such as after chemotherapy. In contrast, leukemia stem cells always rely on this signaling path. The LIGHT/LTbR signaling path is associated with an increase in symmetrical cell division, which leads to the proliferation of leukemia stem cells. If the path is blocked with monoclonal antibodies, etc., leukemia stem cells will lose stem cell function and die. In addition, the number of LIGHT binding points in leukemia stem cells is significantly higher than the normal hematopoietic stem cells. In laboratory experiments, animals with leukemia survived significantly longer when the newly discovered signaling path was blocked.The latest contribution is a ray of hope for future leukemia treatmentthe results of this study show that multiple subjects/hems maintain the participating leukemia stem cells. The researchers believe the new method, blocking LIGHT, could improve the treatment of various types of leukemia in the future.Medications designed to block various immune receptors and mating bodies have led to changes in cancer treatment. However, important drugs used to treat solid tumors are not effective in treating leukemia. Therefore, the CD70/CD27 and LIGHT/LT beta R signaling pathras identified by these researchers are important advances in improving immunotherapy for myeloid leukemia. A team at Stanford University in the United States has developed antibodies targeting CD47 to activate another immune signaling path path (swallowing). These new drugs are already in Phase II development for the treatment of acute myeloid leukemia (AML). (Bio Valley):1. Sabine Höpner et al. LIGHT/LTβR signaling regulates self-renewal and differentiation of hematopoietic and leukemia stem cells. Nature Communications, 2021, doi:10.1038/s41467-021-21317-x.2.Targeted elimination of leukemic stem cells